Global prescription spending reached $1.7T in 2025 (+10% YoY), with 43% concentrated in oncology, immunology, diabetes, and obesity, these are the primary drivers through 2030.
Amid rising patent expiries, biosimilars, and pricing pressures, commercial success depends not just on volume growth, but on converting demand into sustainable revenue through viable pricing, reimbursement, and market access.
Growth is concentrating around a few therapy areas
- Oncology: The primary market driver, projected to grow from $252B (2024) to $441B (2029) via novel mechanisms and expanded indications.
- Immunology: Sustained by biologic adoption, though biosimilar entry is tempering spending growth.
- Diabetes & Obesity: Rapidly expanding through GLP-1 therapies, with peak volume constrained by affordability and reimbursement.
- Neurology: Emerging growth area fueled by pipelines in Alzheimer’s, migraine, and rare disorders.
Commercial viability requires balancing top-line growth against long-term durability, payer access, and competitive intensity.
Patient need does not automatically become pharmaceutical demand
Disease prevalence establishes the potential patient pool. Treatment rates determine the commercial market.
A therapy may address millions of patients but have limited uptake because of diagnostic capacity, physician awareness, treatment guidelines, affordability or reimbursement restrictions. Conversely, a smaller patient population can support substantial pharmaceutical value when treatment intensity and willingness or ability to pay are high.
This makes several variables important when sizing a therapy market:
- Eligible patient population
- Diagnosis and treatment rates
- Treatment duration
- Lines of therapy
- Physician prescribing behaviour
- Payer coverage
- Out-of-pocket affordability
A pharmaceutical market assessment therefore needs to distinguish between epidemiological demand and treated demand.
Competition can change the trajectory of a growing market
Therapy-area growth does not occur in a vacuum.
New product launches can expand the treated population while simultaneously increasing competitive pressure. Established products may lose exclusivity, creating opportunities for generics and biosimilars and changing the economics of the category.
IQVIA expects loss of exclusivity to be one of the major forces moderating global medicine-spending growth through 2030. In immunology, for example, biosimilar availability is expected to constrain spending growth even as medicine use continues to increase.
For pharmaceutical companies, this means market attractiveness needs to be assessed alongside:
- Pipeline intensity: How many competing products are approaching launch?
- Exclusivity: Which major therapies face patent or regulatory exclusivity expiry?
- Clinical differentiation: Does the product offer a meaningful advantage in efficacy, safety, convenience or adherence?
- Substitution: How easily can physicians switch between competing therapies?
A high-growth therapy with heavy upcoming competition can present a very different opportunity from a slower category with stronger product differentiation.
Pricing increasingly depends on the value proposition
List-price growth obscures true commercial opportunity, which is shaped by discounts, rebates, payer negotiations, and local affordability.
With medicines driving 20 to 60% of healthcare costs in developing nations, often paid out-of-pocket, pricing strategy must align ability to pay with clinical alternatives and reimbursement terms to achieve both broad access and commercial viability.
Geographic demand can look very different
Pharmaceutical growth is not evenly distributed across regions.
IQVIA expects medicine-use growth in many emerging and middle-income markets to outpace developed markets, but per-capita utilization remains substantially different across countries. That creates two different opportunities: expanding access to established medicines and commercializing innovative therapies in markets with stronger purchasing power.
Market prioritization should therefore consider:
- Patient population and disease burden
- Current treatment penetration
- Healthcare expenditure
- Reimbursement environment
- Regulatory pathway
- Competitive intensity
- Distribution and access infrastructure
A country with a large untreated population may offer substantial long-term volume potential, while a smaller developed market may generate greater near-term value per patient.
How Nexdigm Assesses Pharmaceutical Markets
Nexdigm evaluates pharmaceutical markets by connecting demand potential with the conditions required to commercialize it. The assessment moves through five stages:
- Market & Therapy Sizing
Nexdigm sizes the market by therapy area, patient population, treatment penetration, prescribing patterns and demand outlook. This establishes where the underlying opportunity is large enough to warrant further evaluation. - Competitive & Pipeline Assessment
The analysis maps incumbent products, market shares, clinical positioning, upcoming launches, patent and exclusivity timelines, and generic or biosimilar exposure. This determines how the competitive landscape could evolve rather than relying only on current market shares. - Pricing & Reimbursement Analysis
Nexdigm evaluates pricing structures, payer coverage, reimbursement mechanisms, tendering and patient affordability. This tests whether potential demand can translate into commercially sustainable revenues. - Market Access & Commercial Feasibility
Regulatory requirements, physician adoption, distribution channels, formulary positioning and healthcare infrastructure are assessed to determine the practical barriers to commercialization in each market. - Market Prioritization & Entry Strategy
The findings are brought together to rank therapy areas and geographies by attractiveness and assess appropriate routes to market, including direct commercialization, partnerships, licensing or distributor-led models.
The result is a market view that connects patient need, competitive dynamics and commercial feasibility, helping pharmaceutical companies decide where to invest, which opportunities to prioritize and how to approach the market.
Nexdigm’s Pharmaceutical Market Assessment
Nexdigm supported a pharmaceutical company in assessing 3 target markets across 2 therapy areas, evaluating market size, demand forecasts, competitive dynamics, pricing, reimbursement and channel readiness. The assessment helped prioritize market opportunities, compare entry models and identify the channel partnerships required for commercialization.
A pharmaceutical market assessment can help companies identify where demand is structurally sustainable, which markets are commercially accessible and where investment is most likely to translate into growth.
To take the next step, simply visit our Request a Consultation page and share your requirements with us.
Harsh Mittal
+91-8422857704
[email protected]